Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tang-Du Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05339581CT.gov IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | — | Unknown | — | — | — |
NCT04134559CT.gov Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT00057980CT.gov Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00058487CT.gov Epirubicin and Thalidomide in Treating Patients With Liver Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epirubicin (this asset) | Tang-Du Hospital | P2 | B · 60 |
| Dexmedetomidine | Uppsala University Hospital | P4 | BBB |
| Adriamycin | Shanghai Zhongshan Hospital | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Idarubicin | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Jnj-54135419 | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Sorafenib | First Affiliated Hospital Xi'an Jiaotong University | P3 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
+42 more in the Liver Cancer cohort
Other indications for Epirubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Inflammatory Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epirubicin in Liver Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/epirubicin-liver-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →